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Alzheimer’s Disease (AD) is the most common dementia in the elderly and is estimated to aﬀect tens of millions of people
worldwide. AD is believed to have a prodromal stage lasting ten or more years. While amyloid deposits, tau filaments, and
loss of brain cells are characteristics of the disease, the loss of dendritic spines and of synapses predate such changes. Popular
preclinical detection strategies mainly involve cerebrospinal fluid biomarkers, magnetic resonance imaging, metabolic PET scans,
and amyloid imaging. One strategy missing from this list involves neurophysiological measures, which might be more sensitive
to detect alterations in brain function. The Magnetoencephalography International Consortium of Alzheimer’s Disease arose out
of the need to advance the use of Magnetoencephalography (MEG), as a tool in AD and pre-AD research. This paper presents
a framework for using MEG in dementia research, and for short-term research priorities.
1. Introduction
Alzheimer’s disease (AD) is the major cause of clinical
dementia in the elderly. As many as 35.6 million people
worldwide may currently be living with dementia, with the
prevalence increasing to 65.7 million by 2030 and 115.4
million by 2050; two thirds of these people will likely have AD
(http://www.alz.co.uk/research/files/WorldAlzheimerReport
-ExecutiveSummary.pdf). The incidence and prevalence of
AD begins to rise as individuals reach the age of 65 so that
by the time they are in their 80 s and 90 s, the risk of clinical
dementia is nearly 50%. However, in spite of the fact that
the risk of the clinical syndrome, Alzheimer’s dementia, is
greatest in the later years of life, the pathological processes,
Alzheimer’s Disease, begin 10–20 or more years before
clinical onset. This means that treatment strategies aimed
at disease modification will be most eﬃcacious if they can
occur during the period when the pathological changes are
occurring, but have not yet exhibited themselves as clinical
signs and symptoms.
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Although the diagnostic criteria for AD have been well
codified since the early 1980s [1–3], there has been a recent
upsurge in interest in studying individuals who are in the
transitional stage between normal cognition and full-blown
dementia. This syndrome, referred to as Mild Cognitive
Impairment (MCI) [4–9], has been the focus of intense study
and there are many who believe that in the absence of other
medical comorbidities, individuals with MCI, in fact, have
clinical AD in its earliest stages [10–13].
At the same time, with the development of new biolog-
ical technologies, there is an increased interest in adding
biomarkers as a form of pathological confirmation of the
clinical diagnosis of AD. The current research diagnostic
standard—those of the NINCDS/ADRDA [1] gives a proba-
bilistic estimate of the risk of pathological AD in the context
of a clinical dementia syndrome. The final diagnosis of
“Definite” AD can only be made in the presence of a suﬃcient
number of senile plaques and neurofibrillary tangles, that
is, a neuropathological examination is required [14–16]. In
life, however, clinical diagnosis is rated in terms of a set of
clear criteria that focus not only on core signs and symptoms,
but also on the presence or absence of comorbid factors that
could, in and of themselves, cause a dementia syndrome. In
the absence of such comorbid conditions, an individual is
thought to have “Probable” AD. When such conditions are
present, then the certainty of diagnosis is reduced to the level
of “Possible”.
Recent attempts at reformulating the diagnostic criteria
have focused on the potential utility of biomarkers including
brain structural and functional imaging, cerebrospinal fluid
measures of amyloid beta, and alterations in brain chemistry
measured using positron emission tomography (PET) [17]
(cf. [18]). Some biomarkers have shown excellent predictive
validity relative to neuropathology including MRI measures
of brain structural integrity, PET and measures of cerebral
blood flow and metabolism. However, “(w)hether one of
these measures or a combination of them is more sensitive
than the other, and whether quantitative values provide
more information than a dichotomous rating are yet to
be determined conclusively” (http://www.alz.org/research/
diagnostic criteria/, accessed 09 Sep, 2010).
Biomarkers measured at the time of the diagnosis of AD
are excellent in predicting the presence of pathology at the
time of autopsy, 8–10 years later. However, they are less
eﬃcient at detecting the presence of pathological change
prior to the onset of clinical symptoms (cf., [19, 20]). This
could be due, in part, to the mechanisms of the initiation
of the molecular cascade leading to amyloid deposition [21].
While PET imaging is particularly useful for measuring brain
metabolism, alterations in amyloid deposits, and in neuro-
chemistry, the temporal and spatial resolution of a PET scan-
ner is such that it reduces its sensitivity to the very early and
statistically small changes in brain function (See Figure 1).
MRI has improved temporal and spatial resolution relative
to PET, but we likely need higher temporal resolution than
is aﬀorded by MR techniques in order to identify the earliest
functional changes of disease in the preclinical stage. Thus,
it seems necessary to have a biomarker that (1) measures
neuronal activity directly, (2) has good temporal and spatial
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Figure 1: Graphic showing the relative spatial and temporal re-
solutions of common neuroimaging techniques (EEG: Electro-
encephalography, IEEG: Invasive Electroencephalography, MEG:
Magnetoencephalography, MRS: Magnetic Resonance Spectrosco-
py, fMRI: functional MRI, SPECT: Single Photon Emission Cranial
Tomography, and PET: Positron Emission Tomography).
resolution, and (3) is able to evaluate functional networks
and the associated neuronal code (i.e., oscillatory activity).
One potential biomarker that has received relatively
little attention is that of electrophysiological/biomagnetic
changes in the brain. These measures are potentially very
useful because although their spatial resolution is similar
to that of MRI, their temporal resolution is as many as
three orders of magnitude better than other existing func-
tional tools. Furthermore, these techniques are noninvasive,
measure neuronal activity directly, and provide valuable
information regarding the frequency of oscillatory activity.
Consequently, these measures may provide the best index
of the earliest functional changes that may occur secondary
to neuropathological processes, but prior to the onset of the
clinical dementia syndrome. In order to be most eﬀective,
however, these markers must have predictive validity relative
to the neuropathology of AD, as well as modest intra-
and intersubject variability. And, they must be stable over
reasonable time course (i.e., 3–6 months) in order to be
useful to track change in disease, or response to medication.
The application of electroencephalography (EEG) in
the clinical evaluation of AD patients has a long tradition
[22, 23], and it is now generally accepted that the EEG in mild
AD is marked by an increase in theta activity, accompanied
by a decrease in beta and alpha activity [24]; more severe AD
is marked by an increase in delta power [25]. This pattern
of results is referred to as the “slowing” of the AD patients’
EEG [26, 27]. Further, it appears that diﬀerences in EEG
abnormalities based on visual ratings may be associated with
diﬀerent cognitive profiles [28]. AD patients with normal
EEGs show the best performance in cognitive tasks, and only
a moderate memory disturbance. Those patients with focal
abnormalities (sharp waves or focal slow-wave activity) had
average performance on the cognitive tasks, with a moderate
alteration in semantic verbal fluency and poor performance
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on the Trail-Making B test. Patients with diﬀuse slowing
only (a dominant frequency below 8 Hz) showed the worst
performance in all tasks. Finally, AD patients with both
focal and diﬀuse EEG abnormalities group showed good
performance in episodic memory tasks and a significant de-
terioration in working memory and executive functions.
EEG has also been investigated in MCI patients, and
a similar pattern of slowing was found. Theta band power
and coherence diﬀers significantly between MCI patients and
healthy subjects [29], and alpha and theta relative power in
the left temporo-occipital derivation correctly classified 85%
of MCI subjects who would later develop AD [30]. A more
anterior localization of theta and alpha activity is also a good
predictor of future development of AD from MCI [31].
Generally, however, MCI subjects tend to show intermediate
EEG parameters between those of ADs and controls. There is
a slowing of the spectral profile in GDS stage 3 (i.e., MCI
subjects), as compared to controls [32]. Patients classified
as GDS 4 or 5 (i.e. clinical dementia) have very similar
profiles to MCI patients; only patients with moderate to
severe dementia had a frequency pattern that was distinct
from all other patients groups. Similarly, increases in theta
and reductions in alpha power can distinguish AD patients
and controls, but cannot distinguish between MCIs and
controls [33]. MCI subjects’ EEG parameters are not only
intermediate between those of controls and AD, but also
show a considerable overlap [27]. Babiloni and colleagues
[34] have suggested that traditional EEG power spectrum
and amplitude analysis might not be sensitive enough to
diﬀerentiate MCI patients from healthy control subjects.
Another method of analysis, estimating coherence/syn-
chronization, is an example of a technique that could
improve classification of MCI. Coherence analysis is widely
used and represents a normalized linear measure of the
correlations between two signals as a function of frequency
[35, 36]. There is a decrease in coherence values in alpha
and beta bands in AD patients (for a review, see [27]). In
the case of MCI, there is a decrease of intrahemispheric
frontoparietal EEG coherence and an increase of temporal
interhemispheric coherence compared to elderly controls.
[37]. Synchronization likelihood (SL) [38] has been used
to study the brain activity in MCI, and was found to be
significantly decreased in the 14–18 and 18–22 Hz bands in
AD patients compared with both MCI subjects and healthy
controls [39]. Unfortunately, SL was similar in the controls
and MCI patients.
Most of resting state EEG studies in MCI show a pat-
tern of increased low-frequency activity accompanied by
a decrease of coherence or synchronization. By contrast,
activation studies tend to show increased SL. In a study of
MCI patients at rest and performing a visual working
memory task, significant diﬀerences between the patients
and controls were found only in the alpha-2 band during the
working memory condition (i.e., not at rest) [40]. Indeed,
there is an increase in SL in MCI during the performance of a
working memory task, and this increase was associated with
the risk for the progression to AD [41]. These paradoxical
findings may be related to a compensatory mechanism in the
brain during the first stages of cognitive deterioration.
Although coherence and SL are probably two of the most
broadly used estimates of EEG connectivity in AD, a variety
of synchronization estimates are being used. For example,
Kramer and colleagues [42] compared phase synchrony and
two measures of nonlinear interdependency in AD patients,
MCI subjects, and healthy controls. Only phase synchrony
and one of the nonlinear estimates allowed the discrimina-
tion of AD patients from controls, and AD and MCI subjects.
None of the measures was capable of discriminating the MCI
patients from the controls. Dauwels and collaborators [43]
tested as many as 20 synchrony measures, on five minutes of
resting EEG data in 25 MCI patients and 56 healthy controls.
Overall, the MCI patients had lower synchronization values
compared to controls, but only two were significant after
correction for multiple comparisons. Those estimates were
the so-called “Full frequency directed transfer function”, and
the ρ parameter of the Stochastic event synchrony. Although
their pattern of results may be due to a disconnection
syndrome in the AD patients, Dauwels and coworkers [43]
highlighted the fact that their results could not be due to
a disconnection syndrome alone (e.g., [44]); the AD patients
showed not only a reduced synchrony but also an increase of
asynchronous activity.
Thus, while EEG provides important information about
AD, it does not appear adequate to detect preclinical disease.
In this paper we will focus on the potential utility of mag-
netoencephalography (MEG) to detect functional changes
in the brain secondary to AD pathology, prior to symptom
onset. MEG is a sensitive tool for measuring magnetic fields
that correspond to electrical currents in the brain, and
that has been extremely useful for non-invasive studies of
epilepsy. MEG technology was born 40 years ago [45] and
has been used for more than 20 years within multimodal
neuroimaging, but only relatively recently has it begun to be
used more extensively in clinical and research settings.
While it is true that MEG it is not a widespread technique,
the number of MEG centers has increased dramatically in
Europe and in America over the last ten years. In the past,
the analysis of MEG data was diﬃcult and required very
specialized methods. More recently, equipment manufac-
turers have developed new software that is relatively user-
friendly allowing physicians to analyze MEG data; there is
new freeware (EEGlab; Brain Storm; SPM8, FieldTrip), and
commercial products (Curry, BESA) are available, as well. It
is still true that for advanced analysis such as connectivity or
network analysis a high degree of analytic specialization is
necessary, but this is a normal stage in the development of
any newer technology.
MEG records activity in the brain based on the magnetic
fields induced by synchronized neuronal currents [46, 47]
and can monitor the activation of synchronously firing
neuronal populations with a submillisecond temporal res-
olution [46–48]. However, since the magnetic signals of
the brain vary between 102 (evoked cortical activity) and
103 femtoteslas (fT) (the human alpha rhythm), and the
magnetic field of the earth is in the neighborhood of 109 fT,
the method has to balance two problems: the weakness
of the signal and the strength of the noise [47]. These
issues are addressed by using hundreds of extremely sensitive
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superconducting quantum interference devices incorporated
in the whole head system (for recording simultaneously from
the entire brain) and used in a magnetically shielded room
[47].
MEG has several advantages over other measures of elec-
trical activity of the brain including its freedom from the
requirement for a reference electrode which has the potential
to improve calculations of the electrical power and source
localization of the signal. Because there is no need for
a reference point in MEG studies, this facilitates synchro-
nization and coherence analyses. Connectivity measures and
source reconstruction solutions depend to some extent on
the positioning of the reference channels, thus the lack of
a reference gives MEG an advantage over EEG. MEG uses
many more detectors than traditional EEG sensor arrays in
many machines, and this can obtain whole head coverage
of signal very rapidly. Because magnetic fields are more
transparent through biological tissue, high-frequency bands
have better signal-to-noise ratios than EEG where electrical
currents are aﬀected by the resistance of biological tissues and
distorted by the skull. This allows for better spatial resolution
and thus better localization of the sources of electrical
activity from MEG compared to EEG. The resistance of the
biological tissues to electrical current also produces severe
attenuation of the EEG signal in the case of the high-gamma
band. MEG, on the other hand, is much more sensitive to
this range of frequencies. In the last decade there is increasing
evidence of the close relation between the gamma band and
cognition.
MEG has several potential advantages over functional
MRI (fMRI), another potential biomarker for AD. First, it
has a much greater temporal resolution, and as one of the
consequences of neurodegeneration is slowed mentation,
this may mean that MEG is better able to measure such
subtle delays in local and regional responses. Second, by
and large, metallic fragments in the body are not contra-
indications for the scan, although if they are large, or are
too close to the head they render the MEG signals too noisy.
Having a 306-sensor, whole head system may allow for easier
comprehensive spatial sampling and thus better suppression
of interference, and advanced processing tools can reduce
unwanted interference [49]. Third, and most important,
is the fact that MEG does not rely on the hemodynamic
response (see [50], for discussion). fMRI measures neuronal
activity only indirectly. When a group of neurons become
activated there is a local increase (about 4000 ms after the
activation) in blood flow which makes it impossible to
measure oscillatory activity in the most relevant frequency
bands. It is the analysis of oscillatory activity aﬀorded by
MEG that allows for the estimation of phase synchronization
indices between brain regions. Intracellular currents in large
neuronal assemblies of at least ∼104-5 pyramidal cells in
parallel orientation can be measured more directly, providing
“a more direct index of sensory, motor, and cognitive task-
specific activation compared with methods that rely on
hemodynamic measures” (page 869, [50]).
One weakness of fMRI and PET activation paradigms is
that the temporal resolution is (relatively) poor. Even with
a rapid fMRI design, the acquisition sums data over 1-2
seconds, and there is a delay of 4–6 seconds between the
relevant neuronal event, and the peak BOLD response. By
contrast, MEG provides nearly simultaneous (with respect
to the neuronal events) recording at >103 msec temporal
resolution. This means that subtle changes are more likely
to be detected, and we have the opportunity for a more
fine-grained analysis of functional connectivity (e.g., [51]).
Alterations in signal characteristics may get lost in the noise
of a 2 second acquisition of fMRI (i.e., TR = 2000),
but may be easily detected with MEG. This high temporal
resolution allows the measurement of the dynamics of the
oscillatory activity, and as a consequence establishing the
functional interaction between brain regions at specific fre-
quency bands. Therefore, MEG provides a four-dimensional
view of brain function (space time frequency connectivity)
which oﬀers a better description of the consequences of
neurological diseases on the functional networks which
support cognitive functions. MEG may have potential as a
biomarker of AD, and we must evaluate the relative merits of
the methodology in neurodegenerative disease.
As noted above, EEG measures of brain function have
shown that the integrity of brain oscillatory activity is a good
index of its functional state. Indeed, over the last several
years, there has been an increase in interest in what is known
as the “default mode network” which was first identified by
using positron emission tomography (PET) and functional
MRI [52]. Although clinical MRI scanners are now capable of
routinely gathering resting state measures of cerebral blood
flow, there is usually no analysis of functional networks
during the “resting” state, as this requires oﬄine processing
(e.g., [53]). This is unfortunate because the “default mode”
appears to be altered in cortical dementias [51, 54, 55]
and such information could be useful diagnostically. While
default mode networks detected with MRI oscillate below
0.5 Hz, resting state measures acquired in MEG can detect
higher frequency oscillations. Dipole density or minimum
current estimates have provided important information
about cortical abnormalities that lead to the clinical progres-
sion of AD [56–58]. Although MEG is relatively less sensitive
to subcortical abnormalities compared to cortical changes,
it can assess function in ∼70% of the fissural cortex, (due
to the alignment of the cortical columns relative to the MEG
sensors). Thus, MEG has a high likelihood of detecting subtle
alterations in cortical function [59].
MEG has already shown promise in terms of detecting
AD in its earliest clinical stage (see [60, 61]). One study of 15
AD patients localized the generators of focal magnetic slow
waves during an eyes-open resting condition using a simple
dipole model [62]. There was an increase in the number
of dipoles in the delta and theta bands, and significant
slowing in brain electrical activity in the temporal and
parietal regions of both hemispheres of the AD patients
[63]. Critically, the slow-wave activity in the right temporal
parietal regions varied as a function of degree of cognitive
impairment, whereas the activity in the left temporal areas
was associated with functional status [62]. The alterations
in brain function that are detected with MEG, especially
those in the temporal regions, are significantly correlated
with the relative volume of the lateral and medial temporal
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lobes [64, 65]. This establishes a link between altered brain
structure and altered brain function measured in two diﬀer-
ent modalities (i.e., MRI and MEG).
MEG may also be useful in aiding with some of the diﬀer-
ential diagnosis that occurs in the context of AD. Specifically,
the “profile” of neuromagnetic activity measured using the
event-related magnetic response in a memory task, includes
significantly reduced activity in the left temporal lobe in AD
patients. By contrast, individuals with late onset depression,
do not diﬀer from nondemented cognitively normal elderly
individuals [66, 67]. Thus, there seems to be some degree of
specificity of the neuromagnetic abnormalities observed in
AD.
MEG shows particular promise in predicting the devel-
opment of MCI from normal cognition. In a study of 15
healthy subjects, five of whom developed MCI two years later,
those who showed cognitive decline had a lower number
of activity sources (400–800 ms frequency range) in the left
medial temporal lobe compared to the individuals who did
not show cognitive decline [68]. Similarly, when individuals
with MCI are studied after two years of followup, the
relative risk of developing AD increased more than three
times among those individuals who had significantly elevated
number of dipole density scores in the delta frequency range
[56]. Taken together these data demonstrate that MEG may
not only be able to predict risk of developing AD from MCI,
but may be able to detect brain functional abnormalities
in cognitively normal individuals. Because MEG is non-
invasive and does not involve the use of contrast agents or
radiotracers, it can be easily repeated as often as necessary as
a method for tracking disease progression.
Critical to understanding the relationships between brain
function and cognition is the concept of functional connec-
tivity. Brain function has been studied from the standpoint
of functional segregation or specialization in an eﬀort to
localize cognitive functions in specific brain regions (see
[69–71] for discussion). Modern views of brain organiza-
tion, when coupled with more advanced statistical analysis
techniques, have allowed us to study the relationship among
brain regions and how they aﬀect behavior [72], that is,
the concept of functional integration studied with functional
connectivity [73]. As such, brain networks represent complex
systemic architecture, with a balance between segregation
and integration of information. Functional connectivity
refers to the statistical interdependence between neurophys-
iological data that is recorded simultaneously from a variety
of diﬀerent brain regions.
Since the early days of modern research in the pathology
of AD, there has been a discussion of concepts of disrupted
connectivity among brain regions as being responsible for
some of the earliest cognitive changes that occur in the disor-
der (e.g., [74]. This disruption of the anatomical/functional
connections in AD led to the idea of a disconnection
syndrome as being potentially responsible for much of the
cognitive loss, at least early in the disease. This abnormality
in functional connectivity suggests abnormal interactions
between neural systems that typically interact to support
cognition and behavior. Because the pathological changes
associated with AD begin several decades before the onset
of the clinical syndromes, it is important to evaluate whether
the functional profiles are aﬀected in the preclinical stages,
including MCI, and even in the context of normal aging.
MEG provides data about three-dimensional space
(space and time), as well as frequency bands, which allows us
to address the question of which areas are functionally linked
(i.e., connectivity), and at what point in the information
processing stream the linkages occur. In MEG, the statis-
tical correlation between two magnetic time series can be
measured through linear and nonlinear methods including
spectral coherence, phase synchronization, or generalized
synchronization. Long-range synchronization between sig-
nals; that is, oscillatory activity, originating in relatively
distant neuronal populations is one potential mechanism
for communication and integration of information in the
brain [75–77]. Thus, functional connectivity can be viewed
as being closely related to the concept of synchrony which
is the most common, economical, and biologically plausible
mechanism for information communication in the brain.
In a recent series of papers examining visual working
memory, Palva and colleagues have demonstrated how
synchrony can support memory [78, 79]. In their studies,
they mapped the dynamics of network synchrony during the
performance of a memory task and found that there was
sustained phase synchrony in parietal/frontal circuits in three
frequency bands. Perhaps most important was the finding
that the synchrony increased as a function of the memory
load. They suggested that the synchrony among the various
brain regions could reflect a compensatory mechanism
to help deal with retention of information, when that
information load rises above working memory “capacity”
(usually in the range of 3-4 items). This is a provocative
finding in the present context because the data suggests that
there is some form of compensatory response possible in the
early stages of MCI and AD [73, 80, 81].
Synchronization Likelihood (SL) has been used to dif-
ferentiate between individuals with AD to subjects with no
cognitive impairment in MEG [39, 51, 82]. These studies
show, in general, a loss of long-distance synchronization in
AD patients. In MCI, similar reductions in long-distance
connections were also noted, even in a resting state. However
during a memory task, patients with MCI showed increased
SL values relative to healthy controls [83]. These latter data
argue against MCI as a disconnection syndrome, but also
must be viewed in the context that there is a functional
compensatory response that occurs during the MCI phase
[81].
The earliest clinical indicators of potential alteration
in brain function can often be symptoms of “subjective
memory complaints” that are not accompanied by alter-
ations in neuropsychological test performance. Patients
with subjective memory complaints showed higher MEG
activation than control subjects in posterior ventral regions
of the cortex, as well as in the parietal/occipital regions [84].
No statistically significant diﬀerences were found between
patients with MCI and individuals with subjective memory
complaints, indicating a certain degree of similarity between
individuals with complaints of memory loss and those with
documented alterations in cognitive functions. This suggests
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at a minimum that within the group of individuals with sub-
jective memory complaints there are some who will progress
to a stage of MCI and eventually AD [85]. Further, in the
earliest preclinical stages of the dementia syndrome, MEG
may be capable of detecting alterations in the functional
organization of the central nervous system that indicate the
existence of a degenerative process.
AD is considered a disease of the cholinergic transmitter
system. This is due in part to the fact that one of the earliest
manifestations of AD pathology is a loss of cholinergic neu-
rons arising from the nucleus basalis of Meynert in the basal
forebrain [86, 87] which can be visualized in structural brain
imaging [88–92]. Indeed, atrophy of the basal forebrain is a
marker for rapid decline from normal cognition to dementia
within four years [93]. Indeed, challenging the cholinergic
system by the administration of scopolamine to cognitively
healthy elders results in greater decline in memory than in
younger individuals [94]. Critical to the present discussion
is the fact that MEG studies have found that spontaneous
brain activity and cortical auditory processing [95] which
are impaired in AD, are themselves modulated by the
scopolamine [96, 97]. Because MEG appears to be sensitive
enough to detect short-term changes in brain activity by
cholinergic modulation it may be useful as a biomarker for
the modulation of the cholinergic system, or of the neural
networks responsible for spontaneous background activity
during the course of a typical pharmacological trial.
As in any other medical procedure MEG needs the
cooperation of the patient to perform an accurate scan. Just
like MRI and PET, patient movement inside the scanner
produces a distortion of the images, which reduces the
utility of the results. For MEG imaging, resting state studies
with MEG require only that the subject is seated (or lying)
in a comfortable position, and remains motionless; MEG
manufacturers have developed head tracking systems to
correct for any inadvertent movements. During cognitive
tasks, it is necessary to acquire a large number of trials so
that the data can be analyzed on a single subject basis, so
there is a necessary tradeoﬀ between time in the scanner and
data acquisition. The large number of trials (normally 120 in
a memory task) allows for an analysis of the within-subject
reliability of the data (i.e., comparing the first half and second
half of the trials), something not generally possible with PET
or fMRI studies.
Before the utility of MEG can be rigorously evaluated in
AD and related dementias, there are some critical prereq-
uisite data that need to be gathered, including determining
the test-retest reliability, and the stability of the signal over
time. That is, in order for MEG to be useful in tracking
the natural history of CNS function, or to be used in
evaluating pharmacotherapy (for example), we must first
understand the extent to which the data are reproducible,
both over the short term (i.e., reliability) and longer term
(i.e., stability). Critically, high reliability and/or stability of
the MEG response are necessary preconditions for MEG
validity. Further, diﬀerent centers must be able to identify
the same biomagnetic signature in order for any putative
biomarker to be useful. Finally, it is equally important to
analyze the reliability and stability of the behavioral task (e.g.,
the modified Sternberg probe task used in many MEG AD
studies) itself. It is critical that the memory task (or other
behavioral probe) is not only reliable, but that any changes
in performance over time are also reflected by changes in
the larger battery of neuropsychological tests (i.e., concurrent
validity).
To date, the bulk of clinically relevant MEG research
uses activation protocols focusing either on somatosensory
functions (e.g., [98]) or, more prominently, language tasks
used in the context of presurgical functional localization
studies [99]. A (relatively) early review of the field [100]
found that MEG was generally reliable and valid (relative
to sodium amytal studies), while source localization varies
within a range of 1.5–3 mm [100] which is less than one voxel
of MRI data. MEG signal reliability for a single region was
rho = .42, and the median correlation across more than 20
regions was .61 (with only one region having a correlation
less than .50) [101]. Thus, at least for language-based tasks,
the ability to localize MEG signal appears good [99].
Once the reliability and stability of MEG are established
for these tasks and patient groups, there must be a demon-
stration that a specific “signature” of AD has concurrent
validity with other known biomarkers such as brain struc-
tural and cerebral metabolism (and amyloid imaging) (e.g.,
[65]). In addition, there should be predictive validity in
that the presence of an abnormality identified by MEG
should correlate with pathological changes in AD identified
at autopsy.
Because MEG has only recently been applied to the study
of neurodegenerative diseases, there are relatively few centers
with the capability and interest in studying the potential
utility of MEG. These centers are widely distributed around
the world adding to the logistic complexity of completing
a study of reliability and stability. However, if such a cross-
center study could be accomplished, this would result in
increased generalizability of the findings as they would have
been acquired on diﬀerent machines in diﬀerent countries
using diﬀerent at-risk populations.
Given this background, we recently formed an inter-
national collaborative group for the study of the utility of
MEG for the preclinical detection of AD. This collaborative
group has the potential to validate previous findings with
MEG, and to demonstrate the suitability of including MEG
in the study of the earliest diagnosis and detection of AD
and related dementias. Three of the centers have extensive
experience studying the capability of MEG in diﬀerentiating
between healthy aging and AD, and as a consequence of
this research there are several principal findings that could
potentially serve as signature biomarkers. These include (1)
a delay in the latency of the N100 m signal which is an index
of stimulus detection; (2) a delay in the mismatch negativity
in auditory cortex as a measure of automatic stimulus
detection and delay of memory trace; (3) an increase in
parietal activity in the delta frequency band in posterior
cortical regions; (4) a reduced number of biomagnetic
sources in the posterior cortical regions during performance
of memory tasks; (5) higher local SL value but lower
long-distance SL values in spontaneous (i.e., resting) brain
activity.
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As a first step in the process of determining the reliability
and validity of MEG in the diagnosis of AD, the collaborative
group will determine the cross-center reliability of mea-
suring biomagnetic signal using standardized techniques,
on the same model equipment, from the same equipment
manufacturer. The protocol includes both resting state (eyes
open, eyes closed), a memory probe task and a mismatch-
negativity task [102]. In addition, all of the subjects
will undergo high-resolution MRI, including anatomical
sequences (i.e., MP-RAGE) as well as those to identify white
matter abnormalities (e.g., FLAIR, DTI). All of the data will
be sent to a central analysis center (Madrid) where they
will be processed (blind) and the results recombined by
an independent data analyst in order to determine center-
to-center reliability. Signal analysis will also be conducted
independently in Helsinki. The data will then be analyzed
in an attempt to replicate not only at a group level, but also
a single subject level. Of particular interest is the extent to
which it is possible to use classification algorithms based
on comparing AD patients and control subjects in order to
identify MCI in the context of healthy aging, something that
will be spearheaded from Pittsburgh (e.g., [103]).
Having established the inter- and intracenter variability,
we will have established a necessary precondition for studies
of concurrent validity relative to the clinical diagnosis, and
to standard measures of brain structural abnormalities (e.g.,
decreased volume of the hippocampus). Having established
these initial standards, only then it will be possible to embark
on large-scale multicenter trials to fully examine the relative
merits of MEG in the diagnosis and early detection of
neurodegenerative pathologies.
Because MEG is a relatively new neuroimaging technol-
ogy and is used extensively only in centers with significant
research operations, it is necessary to establish these criteria
not only on a multisite basis, but also a multinational basis.
No single center will have suﬃcient cases or the analytic
wherewithal to complete the process in isolation. It is only by
virtue of these multinational collaborative eﬀorts that MEG
can be fairly evaluated for potential use in AD.
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